Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Want to make money from home? Discover simple and effective ways to earn cash quickly without leaving your house.
24,232 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
EOS Energy Enterprises sparked a notable move in today’s trading. This article breaks down the possible catalysts beh...
A pivotal Investor Day pushed Schwab stock higher on Friday as management raised guidance on revenue growth and net i...
Could Sandisk stock reach jaw-dropping levels next year? This article breaks down the logic, the risks, and practical...
AI infrastructure relies on powerful chip makers. Here's Taiwan Semiconductor (TSM) emerges as a core holding, combin...
Investors chasing SpaceX-style wins without a private bet must weigh public players carefully. This guide compares AS...
When a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
When a figure headlines with trillionaire status and a big stock sale, investors want to know what it means for the s...
What makes a stock push to all-time highs before the calendar flips? This guide breaks down the catalysts, valuation,...
Investors are watching Micron’s rally with curiosity. This guide explains why micron stock keeps going, what drives t...
A high-profile insider sale at Mineralys raises questions about what it might mean for the biotech's near-term trajec...
Oil shocks are roiling tech-heavy markets, but the Dow Jones keeps a steady hand. This piece breaks down what the spl...